These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 330064)
21. Effect of non-heparin thrombin antagonists on thrombin generation, platelet function, and clot structure in whole blood. Carr ME; Angchaisuksiri P; Carr SL; Martin EJ Cell Biochem Biophys; 2003; 39(2):89-99. PubMed ID: 14515016 [TBL] [Abstract][Full Text] [Related]
22. Thrombin-Hirudin complex formation, thrombin-antithrombin III complex formation, and thrombin generation after intrinsic activation of plasma. Gallistl S; Muntean W Thromb Haemost; 1994 Sep; 72(3):387-92. PubMed ID: 7855789 [TBL] [Abstract][Full Text] [Related]
23. Anticoagulating and non-enzymatic fibrinolytic activities of heparin-antithrombin III and antithrombin III-heparin-thrombin complexes in vitro and in vivo. Kudrjashov BA; Pastorova VE; Lyapina LA Folia Haematol Int Mag Klin Morphol Blutforsch; 1983; 110(5):731-42. PubMed ID: 6198257 [TBL] [Abstract][Full Text] [Related]
24. The effect of antithrombin III-independent thrombin inhibitors and heparin on fibrin accretion onto fibrin-coated polyethylene. Rubens FD; Weitz JI; Brash JL; Kinlough-Rathbone RL Thromb Haemost; 1993 Feb; 69(2):130-4. PubMed ID: 8456425 [TBL] [Abstract][Full Text] [Related]
25. Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma. Okwusidi JI; Anvari N; Kulczycky M; Blajchman MA; Buchanan MR; Ofosu FA J Lab Clin Med; 1991 May; 117(5):359-64. PubMed ID: 2019790 [TBL] [Abstract][Full Text] [Related]
26. Real-time measurement of free thrombin: evaluation of the usability of a new thrombin assay for coagulation monitoring during extracorporeal circulation. Krajewski S; Krauss S; Kurz J; Neumann B; Schlensak C; Wendel HP Thromb Res; 2014 Mar; 133(3):455-63. PubMed ID: 24359968 [TBL] [Abstract][Full Text] [Related]
27. Modulation of heparin cofactor II activity by histidine-rich glycoprotein and platelet factor 4. Tollefsen DM; Pestka CA J Clin Invest; 1985 Feb; 75(2):496-501. PubMed ID: 3838317 [TBL] [Abstract][Full Text] [Related]
28. The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor. Ofosu FA; Cerskus AL; Hirsh J; Smith LM; Modi GJ; Blajchman MA Br J Haematol; 1984 Jun; 57(2):229-38. PubMed ID: 6733045 [TBL] [Abstract][Full Text] [Related]
29. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases. Melo FR; Mourão PA Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401 [TBL] [Abstract][Full Text] [Related]
30. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update. Despotis GJ; Joist JH J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245 [TBL] [Abstract][Full Text] [Related]
31. Impaired inactivation by antithrombin and hirudin and preserved fibrinogen-clotting activity of thrombin in complex with anti-thrombin antibody from a patient with antiphospholipid syndrome. Kolev K; Léránt I; Skopál J; Kelemen A; Nagy Z; Machovich R Thromb Haemost; 2005 Jul; 94(1):82-7. PubMed ID: 16113788 [TBL] [Abstract][Full Text] [Related]
32. [Heparin and antiheparin in young children. 1. Report: development of a method for determining heparin and antiheparin in the antithrombin-thrombin system]. Domula M; Weissbach G Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(5):808-23. PubMed ID: 6188669 [TBL] [Abstract][Full Text] [Related]
33. Formation of activated protein C and inactivation of cell-bound thrombin by antithrombin III at the surface of cultured vascular endothelial cells--a comparative study of two anticoagulant mechanisms. Delvos U; Meusel P; Preissner KT; Müller-Berghaus G Thromb Haemost; 1987 Feb; 57(1):87-91. PubMed ID: 3590084 [TBL] [Abstract][Full Text] [Related]
34. Cleavage of blood coagulation factor XIII and fibrinogen by thrombin during in vitro clotting. Greenberg CS; Miraglia CC; Rickles FR; Shuman MA J Clin Invest; 1985 May; 75(5):1463-70. PubMed ID: 2860124 [TBL] [Abstract][Full Text] [Related]
35. Antithrombin III and heparin inactivation in thrombin involving reactions. Marciniak E Thromb Haemost; 1977 Aug; 38(2):486-93. PubMed ID: 579490 [TBL] [Abstract][Full Text] [Related]
36. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma. Rezaie AR Thromb Res; 2007; 119(4):481-8. PubMed ID: 16515805 [TBL] [Abstract][Full Text] [Related]
37. Antithrombin III. Theory and clinical applications. H. P. Smith Memorial Lecture. Seegers WH Am J Clin Pathol; 1978 Apr; 69(4):299-359. PubMed ID: 347919 [TBL] [Abstract][Full Text] [Related]
38. Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C. Petäjä J; Fernández JA; Gruber A; Griffin JH J Clin Invest; 1997 Jun; 99(11):2655-63. PubMed ID: 9169495 [TBL] [Abstract][Full Text] [Related]
39. The appended tail region of heparin cofactor II and additional reactive centre loop mutations combine to increase the reactivity and specificity of alpha1-proteinase inhibitor M358R for thrombin. Sutherland JS; Bhakta V; Sheffield WP Thromb Haemost; 2007 Nov; 98(5):1014-23. PubMed ID: 18000606 [TBL] [Abstract][Full Text] [Related]
40. A comparison of pentosan polysulphate (SP54) and heparin. I: Mechanism of action on blood coagulation. Fischer AM; Barrowcliffe TW; Thomas DP Thromb Haemost; 1982 Apr; 47(2):104-8. PubMed ID: 6179182 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]